Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 26 · below the Ichimoku cloud · RSI 18 (oversold) · MACD below its signal · 4% above its 52-week low
| 5.63 | 52-week high | +3316.26% |
| 0.6800 | Previous month high | +312.62% |
| 0.2600 | Previous week high | +57.77% |
| 0.2220 | Previous month low | +34.71% |
| 0.2133 | R3 (classic) | +29.45% |
| 0.2017 | R2 (classic) | +22.37% |
| 0.1900 | Previous day high | +15.29% |
| 0.1833 | R1 (classic) | +11.25% |
| 0.1717 | Pivot | +4.17% |
| 0.1648 | Price now | |
| 0.1600 | Previous day low | −2.91% |
| 0.1590 | Previous week low | −3.52% |
| 0.1590 | 52-week low | −3.52% |
| 0.1533 | S1 (classic) | −6.96% |
| 0.1417 | S2 (classic) | −14.04% |
| 0.1233 | S3 (classic) | −25.16% |
None of the 29 investors followed here reported a position in RKDA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RKDA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 2, 2025 | Schaefer Thomas J.Chief Executive Officer | Purchase at price 5.00 per share. | 700 | $3.50K |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.5 | -4.7 | -29.3 | -23.9 | -8.1 | -29.6 | -8.0 | -17.0 | -46.1 | -41.1 | −91.7% | ||
| 2025 | -18.2 | -19.2 | -24.0 | 17.8 | 34.6 | -8.5 | -0.2 | -10.3 | -10.0 | 7.5 | -3.7 | -44.9 | −66.6% |
| 2024 | -23.6 | 19.2 | -22.5 | -7.2 | 49.3 | 2.9 | -12.1 | 12.2 | -12.1 | 41.0 | -27.5 | 112.2 | +89.1% |
| 2023 | -4.1 | -3.8 | -25.3 | -18.3 | -24.8 | -15.5 | 11.9 | -19.4 | -4.3 | 2.3 | -15.4 | 7.9 | −71.1% |
| 2022 | -16.0 | 13.8 | 40.7 | -31.1 | 42.0 | -27.0 | -16.2 | 4.2 | -39.5 | -20.3 | -20.4 | -19.1 | −73.9% |
| 2021 | 8.7 | 15.3 | -13.1 | -3.4 | 6.4 | 4.9 | -20.9 | 3.0 | -14.5 | -5.8 | -33.8 | -19.4 | −58.9% |
| 2020 | -6.6 | -19.5 | -30.8 | 49.1 | -14.4 | 3.3 | -5.3 | -12.4 | -10.3 | 4.6 | 13.7 | -24.0 | −53.8% |
| 2019 | 13.6 | 123.6 | -12.9 | -14.3 | -14.3 | -40.4 | -28.7 | 249.3 | -38.8 | 2.1 | 4.0 | 10.3 | +72.9% |
| 2018 | -0.9 | -18.5 | 440.8 | -48.3 | -7.4 | -28.2 | -22.4 | 7.0 | -28.6 | -17.0 | -0.7 | -21.3 | −42.4% |
| 2017 | 8.7 | -7.2 | -26.5 | -0.3 | 2.9 | -35.7 | 14.4 | -20.4 | 2.9 | -33.6 | -18.9 | 21.1 | −70.1% |
| 2016 | -3.0 | -3.7 | -2.1 | -22.7 | -29.8 | 71.5 | -8.9 | -8.1 | -10.1 | -16.9 | -30.2 | -18.6 | −69.7% |
| 2015 | -26.0 | -33.4 | 53.5 | -53.1 | -8.2 | 40.7 | -22.8 | −64.7% |
No analyst coverage for this instrument.
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.